Arrowhead Pharmaceuticals (ARWR)

Outperform Current rating · 2 reports

Outperform Recap: Q3 FY26

The Left Tail Is Gone: SHASTA Delivers and the Bill for Speed Is $215 Million

Hold Recap: Q2 FY26

The Beat That Wasn't: Arrowhead's Best Operating Quarter Arrives With Two Disclosures Management Left in the 10-Q